Exelixis SG&A Expenses 2010-2025 | EXEL

Exelixis sg&a expenses for the twelve months ending June 30, 2025 were $0.518B, a 0.5% increase year-over-year.

  • Exelixis annual sg&a expenses for 2024 were $0.492B, a 9.32% decline from 2023.
  • Exelixis annual sg&a expenses for 2023 were $0.543B, a 18.02% increase from 2022.
  • Exelixis annual sg&a expenses for 2022 were $0.46B, a 14.47% increase from 2021.

Exelixis SG&A Expenses 2010-2025 | EXEL

  • Exelixis annual sg&a expenses for 2024 were $0.492B, a 9.32% decline from 2023.
  • Exelixis annual sg&a expenses for 2023 were $0.543B, a 18.02% increase from 2022.
  • Exelixis annual sg&a expenses for 2022 were $0.46B, a 14.47% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$237.5B
Amgen (AMGN)$162B
Gilead Sciences (GILD)$142.8B
Vertex Pharmaceuticals (VRTX)$120.5B
Bristol Myers Squibb (BMY)$93.6B
CSL (CSLLY)$84.5B
GSK (GSK)$79.6B
Regeneron Pharmaceuticals (REGN)$59.9B
Alnylam Pharmaceuticals (ALNY)$44.3B
Argenex SE (ARGX)$36.7B
BioNTech SE (BNTX)$26.5B
Royalty Pharma (RPRX)$20.9B
Insmed (INSM)$20B
Biogen (BIIB)$18.6B
Illumina (ILMN)$16.9B
Incyte (INCY)$15B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14.3B
Moderna (MRNA)$12.4B
BioMarin Pharmaceutical (BMRN)$11.3B
QIAGEN (QGEN)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Ascendis Pharma (ASND)$10.2B
Bio-Techne Corp (TECH)$9B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.8B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.7B
Legend Biotech (LEGN)$7.4B
Halozyme Therapeutics (HALO)$7.4B